Kunal Kumar - Publications

Pharmacology Icahn School of Medicine at Mount Sinai, New York, NY, United States 

3 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Ackeifi C, Swartz E, Kumar K, Liu H, Chalada S, Karakose E, Scott DK, Garcia-Ocaña A, Sanchez R, DeVita RJ, Stewart AF, Wang P. Pharmacologic and genetic approaches define human pancreatic beta cell mitogenic targets of DYRK1A inhibitors. Jci Insight. PMID 31821176 DOI: 10.1172/jci.insight.132594  0.48
2018 Kumar K, Man-Un Ung P, Wang P, Wang H, Li H, Andrews MK, Stewart AF, Schlessinger A, DeVita RJ. Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic β-cell proliferation activity. European Journal of Medicinal Chemistry. 157: 1005-1016. PMID 30170319 DOI: 10.1016/j.ejmech.2018.08.007  0.48
2018 Kumar K, Wang P, Sanchez R, Swartz E, Stewart AF, DeVita RJ. Development of Kinase-Selective, Harmine-Based DYRK1A Inhibitors that Induce Pancreatic Human β-Cell Proliferation. Journal of Medicinal Chemistry. PMID 30059217 DOI: 10.1021/acs.jmedchem.8b00658  0.48
Show low-probability matches.